

No.DCG (I)/Misc./2017 (104)
Central Drugs Standard Control Organisation
Directorate General of Health Services
Office of Drugs Controller General India
FDA Bhawan, Kotla Road, New Delhi

Dated:12th September, 2017.


NOTICE

It has come to the notice of the undersigned that certain innovations of National Laboratories/public funded institutions in areas related to new drug development could not fulfill the regulatory requirements for their approval due to various reasons including lack of proper understanding on the laid down regulatory pathways.

In order to facilitate such development, it has been decided to have a system of consultative meetings of these laboratories/institutions with CDSCO to deliberate their cases for proper understanding of the regulatory pathways.

For this purpose, Shri A.K. Pradhan, Dy. Drugs Controller (India), CDSCO has been designated to coordinate these meetings at CDSCO as and when requests from such laboratories/institutions are received. Subject experts in the related field would also be invited on need basis for such meetings.

National Laboratories/public funded institutions involved in research in the area of new drug development are requested to avail this opportunity.


(Dr. G.N. Singh)
Drugs Controller General (India)

To:

1. CSIR/DRDO/National Laboratories
2. CDSCO Website

Copy for information to:

- (i) PPS to DG, CSIR, New Delhi.
- (ii) PPS to DG, DRDO, New Delhi
- (iii) PPS to Principal Scientific Adviser to PM, Vigyan Bhawan, New Delhi.
- (iv) PPS to DGHS, Nirman Bhawan, New Delhi.
- (v) PS to JS (R), Ministry of Health & Family Welfare, Nirman Bhawan, New Delhi.